XXX (2) - Saccharomyces boulardii & Crohn’s disease (CD)

Study overview

It is a randomized, single-center, double-blind, placebo-controlled pilot trial studying Saccharomyces boulardii (S.b.) in a dosage of 250 mg t.i.d., initially for seven weeks in addition to the basic treatment or placebo in 17 randomized patients with Crohn's disease suffering from diarrhea and moderate complaints (1)

Outcome measures

Complaints as measured by the BEST Index, frequency of bowel movements (1)

Results and conclusion

The trial observed a significant reduction in the frequency of bowel movements among the group treated with Saccharomyces boulardii (S.b.) By the tenth week, this group experienced an average of 3.3 ± 1.2 evacuations per day. Additionally, th…